ENDRA Life Sciences Inc.
NDRA· Nasdaq
NDRAENDRA Life Sciences Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001213900-26-090027
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | $159.94K | -$1.23M | -$2.23M | -$2.56M |
| EPS Diluted | $0.06 | -$1.71 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
